Optimized high-performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide

被引:56
作者
Lensmeyer, GL
Gidal, BE
Wiebe, DA
机构
[1] UNIV WISCONSIN HOSP & CLIN,CLIN TOXICOL LAB,DEPT LAB MED,MADISON,WI 53792
[2] UNIV WISCONSIN HOSP & CLIN,SCH PHARM,MADISON,WI 53792
[3] UNIV WISCONSIN HOSP & CLIN,CLIN TOXICOL LAB,DEPT PATHOL,MADISON,WI 53792
关键词
high-performance liquid chromatography; lamotrigine; phenytoin; carbamazepine; solid-phase extractions;
D O I
10.1097/00007691-199706000-00009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Lamotrigine (LG), phenytoin (PY), carbamazepine (CM), and carbamazepine epoxide (CE) are measured with an optimized procedure that uses thin sorbent extraction disks and a highly selective, sterically protected bonded silica high-performance liquid chromatography (HPLC) column. Routinely, serum (200 mu l at pH 6.8 with cyheptamide as internal standard) is applied to an Empore octyl (C-8) solid-phase extraction disk to isolate the drugs. A water wash removes interferences, and the retained drugs are eluted with a small volume of solvent. The eluate is directly injected onto a Zorbax Stable Bond cyanopropyl HPLC column with quantification at 214 nm. Evaporation-concentration steps are unnecessary. overall, for all drugs, between-run precision coefficients of variation (n = 16 each) ranged from 2.1% to 4.9% at concentrations from 0.75 to 20.5 mg/l; extraction recoveries fell within a range of 96% to 110% at concentrations of 2, 10, and 30 mg/l tested for each drug; the lowest limit of detection was 0.15 to 0.35 mg/l, The analytical response was linear for each drug >80 mg/l (LG) and >50 mg/l (PY, CM, and CE). Optimization graphs are presented to illustrate the rationale for selection of test parameters for a robust method. In addition, a comparison study between two commercial laboratories demonstrates accuracy problems associated with LG testing.
引用
收藏
页码:292 / 300
页数:9
相关论文
共 30 条
[1]   COMPARATIVE PHARMACOKINETICS OF THE NEWER ANTIEPILEPTIC DRUGS [J].
BIALER, M .
CLINICAL PHARMACOKINETICS, 1993, 24 (06) :441-452
[2]   VALIDATION OF A RADIOIMMUNOASSAY FOR THE DETERMINATION OF HUMAN PLASMA-CONCENTRATIONS OF LAMOTRIGINE [J].
BIDDLECOMBE, RA ;
DEAN, KL ;
SMITH, CD ;
JEAL, SC .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) :691-694
[3]   PERFORMANCE ANALYSIS OF A REVERSED-PHASE LIQUID-CHROMATOGRAPHIC ASSAY OF LAMOTRIGINE IN PLASMA USING SOLVENT-DEMIXING EXTRACTION [J].
COCIGLIO, M ;
ALRIC, R ;
BOUVIER, O .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1991, 572 (1-2) :269-276
[4]   LAMOTRIGINE, A NEW ANTICONVULSANT - PHARMACOKINETICS IN NORMAL HUMANS [J].
COHEN, AF ;
LAND, GS ;
BREIMER, DD ;
YUEN, WC ;
WINTON, C ;
PECK, AW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (05) :535-541
[5]  
DOIG MV, 1991, J CHROMATOGR, V554, P181, DOI 10.1016/S0021-9673(01)88448-X
[6]   RETENTION MECHANISMS OF BONDED-PHASE LIQUID-CHROMATOGRAPHY [J].
DORSEY, JG ;
COOPER, WT .
ANALYTICAL CHEMISTRY, 1994, 66 (17) :A857-A867
[7]   SIMULTANEOUS DETERMINATION OF ANTIEPILEPTIC DRUGS AND THEIR METABOLITES, INCLUDING CHIRAL COMPOUNDS, VIA BETA-CYCLODEXTRIN INCLUSION COMPLEXES BY A COLUMN-SWITCHING CHROMATOGRAPHIC TECHNIQUE [J].
ETO, S ;
NODA, H ;
NODA, A .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 658 (02) :385-390
[8]   A LIQUID-CHROMATOGRAPHIC ASSAY USING A HIGH-SPEED COLUMN FOR THE DETERMINATION OF LAMOTRIGINE, A NEW ANTIEPILEPTIC DRUG, IN HUMAN PLASMA [J].
FAZIO, A ;
ARTESI, C ;
RUSSO, M ;
TRIO, R ;
OTERI, G ;
PISANI, F .
THERAPEUTIC DRUG MONITORING, 1992, 14 (06) :509-512
[9]   New drugs for the treatment of epilepsy [J].
Fraser, AD .
CLINICAL BIOCHEMISTRY, 1996, 29 (02) :97-110
[10]  
FRAZER A, 1995, THER DRUG MONIT, V17, P174